Jatenzo and Autoimmune Disease: What Clinicians and Patients Need to Know

What Is Jatenzo and How Does It Differ from Other Testosterone Formulations?

Jatenzo is the first oral testosterone product approved in the United States that does not carry a black-box warning for hepatotoxicity. The capsule matrix encases testosterone undecanoate in a castor-oil and lauric-acid lipid vehicle that drives absorption through intestinal lymphatics rather than the portal vein. This bypasses the hepatic first-pass metabolism that made earlier oral androgens, such as methyltestosterone, unsafe for long-term use.

Lymphatic Absorption and Systemic Exposure

Because chylomicron uptake is fat-dependent, Jatenzo must be taken with a meal containing at least 20 to 30 grams of fat [1]. Taking the capsule in a fasted state reduces peak testosterone (C-max) by roughly 45%, a clinically significant reduction that the FDA reviewed in its 2019 approval package [2]. This food-dependency is particularly relevant in autoimmune patients who may experience nausea or reduced appetite from disease flares or from disease-modifying antirheumatic drugs (DMARDs).

Key Trial Efficacy Data

The Swerdloff et al. Study published in the Journal of Clinical Endocrinology and Metabolism (N=166) demonstrated that 87% of men with hypogonadism achieved a serum total testosterone within the normal range (300 to 1000 ng/dL) after 3 months of twice-daily dosing [1]. Mean serum testosterone increased from a baseline of approximately 223 ng/dL to a mid-dose average of 462 ng/dL. Dihydrotestosterone (DHT) also rose, reaching roughly 1.7 times the upper normal limit in some subjects, which the authors noted as a distinguishing feature of the oral undecanoate route compared with transdermal delivery [1].

Testosterone's Immunomodulatory Effects: Mechanisms Relevant to Autoimmune Disease

Testosterone is not immunologically inert. Both androgen receptors (AR) and sex-hormone binding globulin receptors are expressed on T lymphocytes, B lymphocytes, natural killer cells, and macrophages [3]. Understanding how testosterone interacts with these immune populations is central to evaluating Jatenzo for men who have concurrent autoimmune conditions.

Th1/Th2 Balance and Cytokine Profiles

Testosterone generally suppresses pro-inflammatory Th1 cytokines, including TNF-alpha and IFN-gamma, while modestly supporting Th2-skewed responses [4]. In practical terms, this could theoretically reduce inflammatory burden in Th1-dominant diseases such as rheumatoid arthritis (RA) or Crohn's disease, while potentially worsening Th2-dominant conditions like atopic dermatitis. The published evidence base for clinical disease modification by testosterone replacement is thin. A 2021 review in Frontiers in Immunology acknowledged that androgen deficiency in men correlates with elevated inflammatory markers, but randomized controlled trial data confirming that testosterone normalization directly reduces autoimmune disease activity scores remains sparse [3].

Regulatory T Cells and Autoimmune Tolerance

Testosterone promotes the expansion of CD4+CD25+FoxP3+ regulatory T cells (Tregs), which are the immune system's primary brake on autoimmune responses [3]. Treg insufficiency is a recognized pathogenic mechanism in systemic lupus erythematosus (SLE), multiple sclerosis (MS), and type 1 diabetes. Whether Jatenzo-driven testosterone normalization produces a clinically detectable Treg expansion has not been tested in a randomized trial specific to autoimmune populations. However, observational data from the broader TRT literature suggest that serum testosterone below 250 ng/dL is associated with elevated hs-CRP and IL-6 in men with RA [4].

Testosterone and B-Cell Autoreactivity

Androgen receptors on B lymphocytes suppress autoreactive B-cell clones. Men with Klinefelter syndrome, who have chronically low testosterone, show higher rates of SLE than the general male population, which supports the hypothesis that androgen deficiency facilitates B-cell dysregulation [5]. Restoring testosterone to mid-normal range (450 to 600 ng/dL) may reduce autoreactive B-cell output, though this has not been confirmed in a Jatenzo-specific study.

Autoimmune Conditions: Condition-Specific Considerations

The clinical picture varies significantly depending on which autoimmune diagnosis the patient carries. The following condition-specific framework guides how to approach Jatenzo initiation and monitoring.

Rheumatoid Arthritis

Men with RA have a two- to fourfold higher prevalence of hypogonadism than age-matched controls without RA, driven partly by chronic inflammation suppressing the hypothalamic-pituitary-gonadal (HPG) axis [4]. The methotrexate or leflunomide commonly prescribed for RA does not pharmacokinetically interact with testosterone undecanoate at the CYP enzyme level, making Jatenzo a relatively clean option from a drug-drug interaction standpoint. The main monitoring concern is erythrocytosis: both RA-related chronic inflammation and testosterone can raise erythropoietin-driven red cell mass. A baseline and quarterly hematocrit check is necessary. Dose reduction is recommended if hematocrit exceeds 54% per the Jatenzo prescribing information [2].

Systemic Lupus Erythematosus

SLE is far less common in men (roughly 10:1 female predominance), but male SLE patients tend to have more severe renal and cardiovascular manifestations [5]. Low testosterone is documented in male SLE patients, and some observational data suggest that androgen deficiency correlates with higher SLEDAI-2K scores. A small open-label trial using intramuscular testosterone in male SLE patients reported modest improvements in fatigue and SLEDAI scores without significant flare induction [5]. Jatenzo has not been studied specifically in male SLE. Given hydroxychloroquine's minimal CYP involvement, co-prescription is pharmacokinetically safe, but vigilance for fluid retention is warranted given the renal implications of SLE nephritis.

Multiple Sclerosis

Testosterone may reduce neuroinflammation by modulating microglial activation and supporting remyelination through Schwann cell AR signaling [6]. A pilot randomized trial (Gonzales et al., Neuroendocrinology 2004, N=10) found that transdermal testosterone supplementation in men with MS was associated with a reduction in brain atrophy rate as measured by MRI volumetry, though the study was underpowered to draw firm conclusions [6]. Interferon-beta and glatiramer acetate, the most common MS disease-modifying therapies, do not have documented pharmacokinetic interactions with testosterone undecanoate. Natalizumab and the S1P-receptor modulators (fingolimod, siponimod) are also unlikely to interact directly, but any drug that alters lipid absorption could theoretically reduce Jatenzo's chylomicron-dependent uptake.

Inflammatory Bowel Disease

Crohn's disease and ulcerative colitis are mechanistically relevant because gastrointestinal mucosal inflammation can impair fat absorption, the same physiological substrate that drives Jatenzo's bioavailability. Active small-bowel Crohn's disease, particularly ileal involvement, may reduce lymphatic testosterone absorption in an unpredictable and variable manner. Monitoring mid-dose serum T more frequently (every 6 to 8 weeks rather than the standard 3 months) is advisable during IBD flares. Budesonide and systemic corticosteroids used for IBD flares carry independent fluid-retention and erythrocytosis risks that compound those of testosterone [2].

Type 1 Diabetes and Autoimmune Thyroid Disease

Hypogonadism is more prevalent in men with type 1 diabetes (T1D) than in the general population, partially due to autonomic neuropathy affecting the HPG axis [7]. Testosterone replacement in T1D has been associated with modest improvements in insulin sensitivity in some observational analyses. The FDA-approved prescribing information for Jatenzo notes that androgens may decrease blood glucose and increase insulin sensitivity, requiring antidiabetic medication dose adjustments [2]. For men with Hashimoto's thyroiditis or Graves' disease receiving levothyroxine or methimazole, no direct pharmacokinetic interaction with testosterone undecanoate has been identified, though thyroid function should be re-checked at 3 months after TRT initiation because changes in sex-hormone binding globulin (SHBG) can alter free T4 and free T3 levels [7].

Drug-Drug Interactions in Autoimmune Patients on Immunosuppressants

Clinicians managing autoimmune patients on complex immunosuppressive regimens must evaluate Jatenzo's interaction profile carefully. Several commonly used agents carry meaningful interaction signals.

Corticosteroids

Concurrent corticosteroid use (prednisone, methylprednisolone) and testosterone synergistically promote fluid and sodium retention, raising the risk of hypertension and peripheral edema [2]. The Jatenzo REMS program requires baseline blood pressure measurement and monitoring at 3 months and then every 6 months thereafter due to the drug's independent hypertensive signal observed in clinical trials (approximately 5% incidence of treatment-emergent hypertension in the Swerdloff et al. Cohort) [1]. In patients on moderate-to-high-dose corticosteroids, BP monitoring frequency should be increased to monthly.

Cyclosporine and Tacrolimus

Cyclosporine is a CYP3A4 substrate and inhibitor. Testosterone undecanoate is metabolized by CYP3A4 in the intestinal wall and liver for the fraction that does escape lymphatic uptake [2]. Co-administration with cyclosporine may raise testosterone exposure modestly. The converse is also possible: testosterone can increase cyclosporine blood levels, potentially increasing calcineurin inhibitor toxicity (nephrotoxicity, neurotoxicity). Checking cyclosporine trough levels 2 weeks after Jatenzo initiation is a reasonable precaution. Tacrolimus shares a similar metabolic pathway and warrants the same monitoring approach.

Anticoagulants

Testosterone potentiates the anticoagulant effect of warfarin by suppressing the hepatic synthesis of clotting factors II, V, VII, and X [2]. For autoimmune patients on warfarin for antiphospholipid antibody syndrome (APS), a common SLE complication, INR should be checked within 7 to 14 days of Jatenzo initiation or dose change. Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban are also CYP3A4 substrates; co-administration with testosterone may increase DOAC exposure slightly, though the clinical magnitude of this effect is not well-quantified in primary literature to date.

JAK Inhibitors

Tofacitinib, baricitinib, and upadacitinib are increasingly used for RA, psoriatic arthritis, and inflammatory bowel disease. These agents independently carry a risk of polycythemia and, at higher doses, a risk of thrombotic events. Concurrent testosterone use compounds erythrocytosis risk. Hematocrit monitoring every 3 months for the first year is the minimum standard when both a JAK inhibitor and Jatenzo are co-prescribed, with consideration of reducing Jatenzo dose if hematocrit reaches 50%.

Blood Pressure and Cardiovascular Monitoring: The Jatenzo REMS

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for Jatenzo specifically because of hypertension signals identified in clinical trials. This is distinct from the class-wide REMS shared by other testosterone products [2]. Blood pressure elevations of 5 to 10 mmHg were observed in a subset of Swerdloff et al. Trial participants, and the prescribing information states that Jatenzo is contraindicated in men with a history of stroke or myocardial infarction within 6 months unless the benefit clearly outweighs risk [2].

For autoimmune patients, the cardiovascular context is already complicated. Men with SLE carry a 3- to 10-fold increased risk of atherosclerotic cardiovascular disease compared with age-matched controls [5]. Men with RA have approximately a 48% higher risk of first MI compared with controls, based on a large cohort study published in Annals of the Rheumatic Diseases [4]. Adding an agent that may raise blood pressure demands careful baseline risk assessment and a shared decision-making conversation documented in the chart.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends against initiating TRT in men with an uncontrolled cardiovascular condition and suggests reassessing after blood pressure is optimized [8]. This standard applies equally to Jatenzo.

Monitoring Protocol for Autoimmune Patients on Jatenzo

Standard Jatenzo monitoring differs from the monitoring appropriate for autoimmune co-morbidity. The table below outlines a practical schedule.

| Parameter | Standard Jatenzo | Autoimmune Overlay | |---|---|---| | Serum testosterone (mid-dose) | Weeks 6, then 3 months | Same; add trough if IBD flare | | Hematocrit | Baseline, 3 months, then every 6 months | Every 3 months if on JAK inhibitor or corticosteroid | | Blood pressure | Baseline, 3 months, every 6 months (REMS) | Monthly if on corticosteroids | | Lipids (LDL, HDL, TG) | Baseline, then annually | Baseline, 3 months, then annually | | PSA | Baseline, 3 months, then annually in men 55+ | Same | | Cyclosporine or tacrolimus trough | Not applicable | 2 weeks post-initiation | | INR (if warfarin) | Not applicable | 7 to 14 days post-initiation or dose change | | Disease-activity score (e.g., DAS28, SLEDAI-2K) | Not applicable | Every 3 months | | Thyroid function (if Hashimoto's or Graves') | Not applicable | 3 months post-initiation |

Initiating Jatenzo in Autoimmune Patients: A Step-by-Step Approach

Starting Jatenzo in a man with active autoimmune disease requires coordination between the prescribing endocrinologist or urologist and the rheumatologist, neurologist, or gastroenterologist managing the underlying condition.

Step 1: Confirm True Hypogonadism

The Endocrine Society defines biochemical hypogonadism as a morning total testosterone below 300 ng/dL on two separate measurements, confirmed with a validated immunoassay or liquid chromatography-tandem mass spectrometry (LC-MS/MS) [8]. Inflammatory states can transiently suppress LH and testosterone. Confirm that low testosterone persists during a period of relative disease quiescence before committing to long-term therapy.

Step 2: Rule Out Hormone-Sensitive Malignancy

Testosterone replacement is absolutely contraindicated in men with known or suspected prostate cancer or male breast cancer [2]. PSA should be checked at baseline. For men on immunosuppressants that could mask prostate cancer symptoms (such as high-dose corticosteroids that blunt PSA rise), a digital rectal exam and urology consultation are advisable before initiation.

Step 3: Optimize Disease Activity and Blood Pressure

Jatenzo should ideally be started when the autoimmune condition is stable, not during a flare. Uncontrolled hypertension (systolic above 160 mmHg) should be addressed before initiation given the Jatenzo REMS requirements [2].

Step 4: Start at 237 mg Twice Daily and Titrate

The starting dose recommended in the prescribing information is 237 mg twice daily with food [2]. After 6 weeks, a mid-dose serum testosterone (obtained 4 to 6 hours after the morning dose) guides dose adjustment. The dose may be decreased to 158 mg twice daily if testosterone exceeds 1000 ng/dL or increased to 396 mg twice daily (two 198-mg capsules) if it remains below 300 ng/dL, always within the approved range.

Step 5: Coordinate Immunosuppressant Monitoring

Communicate the Jatenzo start date to all co-prescribers. Flag cyclosporine and tacrolimus for trough re-checking, warfarin for INR, and JAK inhibitors for hematocrit surveillance as outlined above.

Special Populations Within the Autoimmune Category

Hypogonadism Secondary to Chronic Inflammation (Functional Hypogonadism)

Chronic systemic inflammation suppresses GnRH pulsatility, reducing LH-driven testosterone synthesis. This is sometimes called "functional" or "inflammatory" hypogonadism to distinguish it from primary testicular failure. The Endocrine Society guideline cautions against initiating TRT in functional hypogonadism without first addressing the underlying cause [8]. For autoimmune patients, optimizing disease control with DMARDs may partially restore HPG axis function, potentially reducing the testosterone dose needed or even removing the need for TRT entirely. Re-evaluating serum testosterone after 6 months of improved disease control is reasonable before committing to indefinite Jatenzo therapy.

Men on Long-Term Glucocorticoids

Prednisone at doses of 7.5 mg/day or higher, sustained for 3 months or more, is an independent cause of hypogonadism through suppression of the HPG axis and direct inhibitory effects on Leydig cell steroidogenesis [9]. In this population, Jatenzo addresses a double pathology: glucocorticoid-induced androgen deficiency plus any residual disease-related HPG suppression. The interaction between corticosteroids and testosterone on fluid retention and cardiovascular parameters requires the intensified BP and hematocrit monitoring schedule described above.

Sjögren's Syndrome

Androgen deficiency is well-documented in primary Sjögren's syndrome, affecting both the lacrimal and salivary gland androgen receptor axis. Male patients with Sjögren's and concurrent hypogonadism may note worsening dry-eye and dry-mouth symptoms as androgen levels decline [10]. While topical androgen formulations exist for dry eye, systemic testosterone normalization with Jatenzo could theoretically support lacrimal gland secretory function. No randomized trial has tested this in male Sjögren's patients specifically.

Patient Counseling Points Specific to Autoimmune Disease

Men with autoimmune conditions need specific counseling beyond the standard Jatenzo patient information sheet.

First, fatty meals are non-negotiable. Disease flares, medication-induced nausea, or dietary restrictions for IBD management can inadvertently convert a therapeutic dose into a subtherapeutic one by eliminating the fat needed for lymphatic absorption [1]. Patients should keep a small supply of fat-containing foods available, such as peanut butter or a handful of nuts, specifically for times when a full meal is not possible.

Second, unexplained worsening of autoimmune symptoms in the first 3 months does not automatically mean Jatenzo caused a flare. Testosterone's immunomodulatory effects take weeks to manifest, and symptom worsening early in the course is more likely to reflect natural disease variability than a drug-induced change in immune tone.

Third, patients should inform all treating providers of the new prescription. The interactions with warfarin, cyclosporine, and tacrolimus are not universally known to sub-specialists outside endocrinology and pharmacy.